.css-1gu7o1h p{color:#FFFFFF;font-weight:600;font-size:1rem;}.css-1gu7o1h .typo{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-box-pack:center;-ms-flex-pack:center;-webkit-justify-content:center;justify-content:center;}.css-1hgicv7{box-sizing:border-box;-webkit-flex-direction:row;-ms-flex-direction:row;flex-direction:row;}.css-1hgicv7 p{color:#FFFFFF;font-weight:600;font-size:1rem;}.css-1hgicv7 .typo{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-box-pack:center;-ms-flex-pack:center;-webkit-justify-content:center;justify-content:center;}

JavaScript is currently disabled in your browser. For the best experience, please enable JavaScript to enjoy full website functionality. Thank you!

Steps to Enable JavaScript

Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients

About the study

This study will assess the serum uric acid lowering effect and safety of AR882 in gout patients at two doses compared to placebo over 12 months

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.

Call +1 858-437-9123

Email Study Center

Study’s details

Age (in years)

18 - 85

Phase

PHASE3

Participants needed

750

Treatment type

INTERVENTIONAL

Sponsor

Arthrosi Therapeutics

ClinicalTrials.gov identifier

NCT06439602

Study number

AR882-302

Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?